Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website. We are a privately held clinical-stage biopharmaceutical company. Our mission is to discover and develop novel CNS drugs as ion modulators and neuroprotectors.

Media

Press Releases - latest

ION CRAFT Project co-funded by the European Commission and coordinated by Newron Pharmaceuticals is being successfully completed.

23/11/2006
   

Newron Pharmaceuticals Strengthens its Board of Directors

23/11/2006
   

Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide

16/10/2006
English Eng   

Newron Pharmaceuticals’ lead clinical program confirms efficacy and safety in a Phase III trial for Parkinson’s disease - Safinamide demonstrates benefit on motor symptoms and Activities of Daily Living as well as good tolerability; improvement in cognition broadens potential scope -

19/06/2006
   

Newron Pharmaceuticals Completes €30 Million Series B Financing - TVM invests in second closing of HBM-led financing

05/10/2005
   

Newron Pharmaceuticals Reports New Data Indicating that its Novel ION Channel Blocker, Ralfinamide, May have Preemptive and Palliative Analgesic Potency Against Spontaneous Neuropathic Pain

14/09/2005
   

Newron Pharmaceuticals Completes Enrollment in Safinamide Phase III Pivotal Clinical Trial for Parkinson’s Disease

21/07/2005
   

Newron Pharmaceuticals Completes Management Team with Appointment of Chief Financial Officer and Chief Medical Officer

04/05/2005
   

Newron Pharmaceuticals Raises €30 Million

21/02/2005
   

Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome

11/01/2005